Eyde, Sarah
Eli Lilly (United States)
2 papers on CoChat
Most cited papers
- Verified
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 184
- Verified
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 132
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free